Clinuvel Pharmaceuticals Stock Earnings Reports

CLINUVEL reported a strong FY2025 with revenue rising 10% to $105M, marking the ninth consecutive annual profit and an eighth consecutive dividend (the fourth fully franked). Commercial sales grew 6% (U.S. and Europe) and sales reimbursements grew 24%; U.S. expansion included 104 trained sites with a target of 120 by year-end. Term deposit interest income rose 29%, and the group remains debt-free with cash reserves up ~22% (~$40M), providing multi-year runway and optionality for R&D and selective M&A. Total expenditure increased 20% as planned, driven by reinvestment in personnel (+31%), R&D (notably the fully recruited Phase III CUV105 vitiligo trial), and communications/brand building (CBM +100%). Management reiterated a disciplined 3-year budget (targeted annual spend ~$50–55M) and highlighted key near-term catalysts: Health Canada decision on SCENESSE, regulatory updates on vitiligo in late 2025, and the first CUV105 readout in H2 2026. The company is advancing other programs (CUV107, ACTH generic NEURACTHEL, porphyria variants) and progressing a photocosmetics program with a multi-year safety/toxicology pathway. Management emphasized preserving shareholder value by self-funding multiple programs without dilution and exploring efficiency/vertical-integration opportunities.